Valuation: Sensorion

Market Cap 140M 159M 130M 119M 224M 15.32B 228M 1.54B 603M 7.53B 597M 584M 26.05B P/E 2026 *
-18.1x
P/E 2027 * -4.18x
Enterprise Value 7.75M 8.82M 7.2M 6.61M 12.42M 849M 12.61M 85.55M 33.42M 418M 33.11M 32.4M 1.44B EV / Sales 2026 *
0.35x
EV / Sales 2027 * 21.9x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
1 day+1.50%
1 week+4.42%
Current month+14.80%
1 month+12.66%
3 months-28.27%
6 months-9.50%
Current year-19.44%
1 week 0.25
Extreme 0.2475
0.28
1 month 0.22
Extreme 0.222
0.28
Current year 0.22
Extreme 0.222
0.81
1 year 0.22
Extreme 0.222
0.81
3 years 0.15
Extreme 0.1544
1.04
5 years 0.15
Extreme 0.1544
2.29
10 years 0.15
Extreme 0.1544
7.74
Manager TitleAgeSince
Chief Executive Officer 59 01/06/2026
Director of Finance/CFO - 26/06/2024
Chief Tech/Sci/R&D Officer - 11/12/2023
Director TitleAgeSince
Director/Board Member - 09/03/2015
Director/Board Member 43 -
Chairman 61 30/03/2023
Date Insider Type Main position Quantity % Market Cap.
6/2/26
Redmile Biopharma Investments III LP
BuyCompany 18,928,571 6.2956%
31/1/26
Sofinnova Partners SAS
BuyCompany 10,714,285 3.5636%
18/4/24
Redmile Biopharma Investments III LP
BuyCompany 2,781,914 1.0091%
Change 5-day change 1-year change 3-year change Capi.($)
+1.50%+4.42%-20.15%-18.35% 157M
+1.07%-3.49%-3.25%+12.87% 46.35B
+0.25%+1.65%+408.41%+629.49% 40.13B
-0.27%+4.45%+9.93%+66.92% 36.33B
+0.35%+0.87%+3.60%-8.81% 34.6B
+3.14%+1.02%+3.37%+38.15% 26.77B
-0.73%+11.84%+31.97%+143.53% 16.91B
+0.47%-2.74% - - 16.66B
+0.42%-5.52%+0.76%+8.50% 13.05B
-2.68%-2.49%-15.00%-31.68% 13.05B
Average +0.35%+1.33%+46.63%+93.40% 24.4B
Weighted average by Cap. +0.46%+1.10%+75.50%+136.91%

Financials

2026 *2027 *
Net sales 21.86M 24.89M 20.33M 18.65M 35.05M 2.4B 35.59M 241M 94.31M 1.18B 93.42M 91.41M 4.07B 6.4M 7.28M 5.95M 5.46M 10.25M 701M 10.41M 70.62M 27.59M 345M 27.33M 26.74M 1.19B
Net income -4.34M -4.94M -4.04M -3.7M -6.96M -476M -7.07M -47.93M -18.72M -234M -18.55M -18.15M -809M -50.64M -57.66M -47.09M -43.21M -81.2M -5.55B -82.45M -559M -218M -2.73B -216M -212M -9.44B
Net Debt -132M -150M -123M -113M -212M -14.47B -215M -1.46B -570M -7.12B -564M -552M -24.6B -
Logo Sensorion
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
63
Date Price Change Volume
24/07/26 EUR 0.2715 +1.50% 671,960
23/07/26 EUR 0.2675 +2.88% 1,312,807
22/07/26 EUR 0.2600 -0.19% 494,468
21/07/26 EUR 0.2605 +5.25% 572,499
20/07/26 EUR 0.2475 -4.81% 483,614
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
0.2715EUR
Average target price
1.240EUR
Spread / Average Target
+356.72%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALSEN Stock